Cell-Free Biomanufacturing Patents: Leaders, Trends & White Space 2026
- One assignee, 249 families. far ahead of the fifth-place filer at 36 and tenth place at 30 — this field has a single dominant claimant rather than a crowded top tier.
- Filing peaked in 2017 at 42 records and 2021-to-2024 volume fell 35% (31 to 20); 2025 onward is still filling in as publications lag filing by about 18 months.
- C12N covers 64.1% of the 696 records in scope while C11B (fatty oils/waxes production) sits at just 11.2% — a narrower, more open branch relative to the microorganism/genetic-engineering core.
Filing growth compares 2021 (31 records) with 2024 (20) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What the cell-free biomanufacturing patent record actually shows
Cell-free biomanufacturing replaces the living cell with its molecular machinery in isolation — extracts, purified enzymes, or reconstituted pathways run outside a membrane. The patent record in scope here spans 2015 to the 2026 cut-off and concentrates around genetic constructs, enzyme-driven synthesis and the fatty-acid and peptide chemistries that dominate early commercial interest. Filing activity is not evenly spread: a single organisation holds a lead position built on a cluster of co-assigned filings with agricultural-research partners, while the rest of the ranked field is a long tail of smaller, often single-filing entrants.
The technology composition points to a field still organised around core molecular-biology claims (C12N, C07K) rather than downstream process engineering. Fermentation and enzymatic synthesis (C12P) and fatty-oil production (C11B) carry meaningfully fewer records, which is where a freedom-to-operate review should look first before assuming the space is occupied.
Filing trend and technology composition
Every figure below is drawn directly from the 696 published records in scope; publication lag means the final one or two years will revise upward as more filings publish.
Filings rose to a 2017 peak, then cooled through the last complete years
Annual filings hit their high point in 2017 at 42 records. Using the window the dataset flags as reliable, 2021 filings (31) fell to 20 by 2024 — a 35% decline over that three-year span. Years after 2024 are still incomplete because publication trails filing by roughly 18 months, so they should not be read as a further drop.
Claim density sits heavily in molecular biology, not process engineering
C12N (microorganisms and genetic engineering) appears in 64.1% of the 696 records, and C07K (peptides and proteins) in 44.3% — together the two largest classes by a wide margin. A61K (25.0%), A01H (21.3%) and C12Q (18.8%) form a second tier tied to therapeutic and plant-breeding applications. C12P (fermentation/enzymatic synthesis, 17.1%) and C11B (fatty oils and waxes, 11.2%) are the smallest classes tracked, and both sit closer to actual production process claims than the dominant genetic-engineering classes do.
Shares are the percentage of the 696 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Cell-Free Biomanufacturing Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about cell-free biomanufacturing patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records and a representative filing
US20150259664A1 — Proteolytic inactivation of select proteins in bacterial extracts for improved expression
The disclosure covers modified proteins engineered with an OmpT1 protease cleavage site in an exposed surface motif, the nucleic acids encoding them, bacterial cells expressing them, and cell-free synthesis systems containing modified RF1. It sets out methods for reducing a modified protein's deleterious activity by exposing it to OmpT1, for cutting RF1 competition at an amber codon, and for expressing a target protein under these conditions.Filed by Sutro Biopharma, Inc. — a core cell-free expression-system patent rather than a downstream application claim.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2010057246A1 | Enzymes and methods for producing omega-3 fatty acids | 168 |
| 2 | WO1999027111A1 | Desaturase genes and their use | 168 |
| 3 | WO2013185184A2 | Production of long chain polyunsaturated fatty acids in plant cells | 139 |
| 4 | US20130274129A1 | TAL-effector assembly platform, customized services, kits and assays | 124 |
| 5 | WO2009129582A1 | Polypeptides and methods for producing triacylglycerols comprising modified fatty acids | 86 |
| 6 | WO2001005808A2 | In vitro selection and optional identification of polypeptides using solid support carriers | 73 |
| 7 | US8809559B2 | Enzymes and methods for producing omega-3 fatty acids | 67 |
| 8 | US20110218348A1 | Polypeptides and methods for producing triacylglycerols comprising modified fatty acids | 66 |
| 9 | WO2013023251A1 | Soluble polypeptides | 65 |
| 10 | US8816111B2 | Lipid comprising polyunsaturated fatty acids | 64 |
Citation counts are a signal of influence within this searched corpus and skew toward older filings — they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the concentration and citation data mean for a filing strategy
Read together, the assignee ranking, the citation table and the class composition point to a field led by one organisation's fatty-acid and plant-trait work, with the underlying cell-free enzymatic and expression-system claims still comparatively open.
One organisation, then a steep drop-off
The leading assignee's family count (249) is more than six times the fifth-place filer's (36), and the strongest co-assignee pair links the same leader to an agricultural-research partner across 152 shared families. This is not a competitive top tier — it is a single dominant program plus a long tail.
Foundational fatty-acid and desaturase patents still anchor the field
The two most-cited records — on omega-3 fatty acid enzymes and desaturase genes — both carry 168 citations and predate the 2015 window, meaning current filers are still building around, not past, this foundational IP.
Volume cooled through the last complete filing years
Filings fell from 31 in 2021 to 20 in 2024, a 35% decline over three years, after peaking at 42 in 2017. Years beyond 2024 are still filling in due to publication lag and should not be read as confirming a further slide.
Genetic-engineering claims dwarf production-process claims
C12N appears in nearly two-thirds of records while C11B, the class closest to actual fatty-oil production process work, appears in just over a tenth. That gap is where process-level claims — as opposed to construct and pathway claims — remain comparatively thin.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to cell-free biomanufacturing patent landscape, with the prior art for and against each one.
Who is filing, and where momentum has stalled
The ranked field of 100 companies is dominated by one assignee's program; recent-year filing counts across the tracked names show the entire group, leader included, filing at most once in the latest year.
A single program built on agricultural co-filing
The top-ranked assignee's position rests substantially on co-assigned families with an agricultural-research partner (152 shared families) and a nutrition-focused affiliate (46 shared families with each of two other parties) — a coordinated program rather than isolated filings.
Most ranked assignees hold single-digit multiples of the median, not the leader's scale
By the tenth position, family counts have already fallen to 30 — roughly an eighth of the leader's 249 — and the ranking continues down to single-digit and single-filing entrants, consistent with a field where entry is easy but scale is rare.
Even the leader shows minimal latest-year activity
Recent-year momentum across the tracked assignees, including the leader, shows at most one filing in the latest tracked year for any of them — expected given publication lag, but a reminder that current-year rankings will shift once 2025–2026 filings finish publishing.
| Assignee | Recent year | YoY |
|---|---|---|
| Commonwealth Scientific and Industrial Research Organisation (CSIRO) | 1 | — |
| Grains Research & Development Corporation | 0 | — |
| Nuseed Pty Ltd | 0 | — |
| Affinium Pharmaceuticals Inc | 0 | — |
| Amicus Therapeutics Inc | 0 | — |
| Rehm Bernd Helmut Adam | 0 | — |
| SINGH SURINDER PAL | 0 | — |
| Sutro Biopharma, Inc. | 0 | — |
Where to take this analysis
The dataset points to a field with one dominant program, a foundational citation base built before 2015, and process-level claim space that is comparatively less occupied than the genetic-engineering core.
Map the co-assignee network in detail
The strongest co-assignee links run through one agricultural-research partnership; a fuller network map would show whether other cross-filing clusters are forming lower in the ranking.
Explore assignee networks in EurekaTest claim scope in the under-claimed classes
C11B and C12P carry the lowest shares of the eight tracked classes, which is where a new process-level filing is least likely to run into dense prior art from the dominant assignee's construct claims.
Run a freedom-to-operate check in EurekaCommon questions on the cell-free biomanufacturing patent landscape
One assignee leads the ranked field of 100 companies with 249 patent families, well ahead of the fifth-place filer at 36 and tenth place at 30. That lead is built substantially on co-assigned filings with an agricultural-research partner, with which it shares 152 families, and a nutrition-focused affiliate with which it shares 46 families in two separate pairings. Below the leader, the field thins quickly into a long tail of smaller and single-filing entrants, so this is not a competitive top tier in the usual sense — it is one dominant program plus many minor players.
Filing peaked in 2017 at 42 records and, over the most recent three-year span the data can reliably support, fell from 31 filings in 2021 to 20 in 2024 — a 35% decline. Figures for 2025 and 2026 are still incomplete because publication typically lags actual filing by around 18 months, so they should not yet be read as confirming a continued fall. Anyone tracking this trend going forward should expect the 2025–2026 counts to revise upward as more records publish.
The dominant classes are C12N (microorganisms and genetic engineering, 64.1% of the 696 records in scope) and C07K (peptides and proteins, 44.3%), reflecting a field still centred on genetic constructs and molecular components. A61K (medicinal preparations), A01H (plant breeding) and C12Q (enzyme/DNA testing) form a second tier each covering roughly a fifth to a quarter of records. C12P (fermentation and enzymatic synthesis) and C11B (fatty oils and waxes production) are the smallest tracked classes, at 17.1% and 11.2% respectively, and are the closest proxies for actual production-process claims rather than construct or pathway claims.
The clearest opening is in process-level claims rather than construct or pathway claims: C11B (fatty-oil production process) and C12P (fermentation and enzymatic synthesis process) carry the lowest shares among the eight tracked classes, at 11.2% and 17.1% of the 696 records respectively, against 64.1% for the core genetic-engineering class. That gap suggests scale-up, vessel and process-parameter claims around cell-free enzymatic systems are less densely claimed than the underlying genetic constructs and pathways themselves. A first filing there would do well to anchor on a specific production-process parameter rather than a new pathway or construct, since those are already crowded.
US20150259664A1, filed by Sutro Biopharma, covers proteins modified with an OmpT1 protease cleavage site inserted into an exposed surface motif, plus the nucleic acids, bacterial cells and cell-free synthesis systems built around them. It specifically blocks methods that reduce a modified protein's deleterious activity via OmpT1 cleavage and methods that reduce RF1 competition at an amber codon within a cell-free expression system. Anyone using a cell-free system with modified RF1 and an engineered OmpT1 cleavage site for expression control would need to review this filing's claim scope before proceeding; workarounds would need to avoid that specific cleavage-site/RF1-competition mechanism.
Research Cell-Free Biomanufacturing Patent Landscape in depth with Eureka
Go past this page: query the whole cell-free biomanufacturing patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.